Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

Check the time stamp on this data. Updated AI-Generated Signals for Avidity Biosciences Inc. (RNA) available here: RNA.

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

A team of researchers at Kumamoto University has uncovered a mechanism in the formation of harmful protein aggregates that ...

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision ...

The innate immune system is the body’s first line of defence against pathogens like bacteria or viruses. TRIM25 is a protein ...

A study from Kumamoto University reveals that G-quadruplex RNA structures facilitate the aggregation of α-synuclein, a ...

B.Riley Financial analyst Madison Elsaadi has reiterated their bullish stance on WVE stock, giving a Buy rating on October 31. Madison Elsaadi ...

HG202 is the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only clinical-stage RNA-targeting therapy for nAMD. “This open IND for HG202 by the US FDA – the first regulator to have cleared ...

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...